Nano-Cap Spruce Biosciences Collaborates With HMNC Brain Health To Develop Treatment for Major Depressive Disorder
Portfolio Pulse from Vandana Singh
Spruce Biosciences Inc. (NASDAQ:SPRB) has entered into a collaboration with HMNC Brain Health GmbH to develop tildacerfont, an investigational product candidate, and HMNC's Cortibon Genetic Selection Tool for treating major depressive disorder (MDD). The collaboration includes a Phase 2 proof-of-concept study funded by HMNC, with Spruce having the option to in-license exclusive worldwide rights to Cortibon if the study results are positive.
June 04, 2024 | 11:02 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Spruce Biosciences has partnered with HMNC Brain Health to develop tildacerfont and Cortibon for major depressive disorder. A Phase 2 proof-of-concept study will be conducted, and Spruce has the option to in-license exclusive worldwide rights to Cortibon if the study results are positive.
The collaboration with HMNC Brain Health and the upcoming Phase 2 study are significant developments for Spruce Biosciences. Positive study results could lead to exclusive worldwide rights to Cortibon, enhancing Spruce's product portfolio and market potential. This news is likely to positively impact SPRB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100